Nitric oxide as a mediator of estrogen effects in osteocytes

Vitamins and Hormones

Volumn 96, Issue , 2014, Pages 247-263

  Joshua, Jisha ^a   Kalyanaraman, Hema ^a   Marathe, Nisha ^a   Pilz, Renate B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

17 Estradiol; Apoptosis; CGMP dependent protein kinases; Nitric oxide; Osteoblasts; Osteocytes; Osteoporosis

Indexed keywords

ESTROGEN; NITRIC OXIDE;

ANIMAL; BONE; BONE DEVELOPMENT; CYTOLOGY; METABOLISM; OSTEOCYTE; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; ESTROGENS; NITRIC OXIDE; OSTEOCYTES;

EID: 84906830780     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800254-4.00010-6     Document Type: Chapter

References (76)

1. Afzal F., Polak J., Buttery L. Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity. Journal of Pathology 2004, 202:503-510.
2. Aguirre J., Buttery L., O'Shaughnessy M., Afzal F., de Marticorena I.F., Hukkanen M., et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. American Journal of Pathology 2001, 158:247-257.
3. Almeida M., Han L., Martin-Millan M., Plotkin L.I., Stewart S.A., Roberson P.K., et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. Journal of Biological Chemistry 2007, 282:27285-27297.
4. Almeida M., Martin-Millan M., Ambrogini E., Bradsher R., Han L., Chen X.D., et al. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. Journal of Bone and Mineral Research 2010, 25:769-781.
5. Armour K.E., Armour K.J., Gallagher M.E., Godecke A., Helfrich M.H., Reid D.M., et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001, 142:760-766.
6. Barrett-Connor E., Grady D., Stefanick M.L. The rise and fall of menopausal hormone therapy. Annual Review of Public Health 2005, 26:115-140.
7. Blaise G.A., Gauvin D., Gangal M., Authier S. Nitric oxide, cell signaling and cell death. Toxicology 2005, 208:177-192.
8. Casteel D.E., Zhuang S., Gudi T., Tang J., Vuica M., Desiderio S., et al. cGMP-dependent protein kinase I β physically and functionally interacts with the transcriptional regulator TFII-I. Journal of Biological Chemistry 2002, 277:32003-32014.
9. Chae H.J., Chin H.Y., Lee G.Y., Park H.R., Yang S.K., Chung H.T., et al. Carbon monoxide and nitric oxide protect against tumor necrosis factor-alpha-induced apoptosis in osteoblasts: HO-1 is necessary to mediate the protection. Clinica Chimica Acta 2006, 365:270-278.
10. Chae H.J., Park R.K., Chung H.T., Kang J.S., Kim M.S., Choi D.Y., et al. Nitric oxide is a regulator of bone remodelling. Journal of Pharmacy and Pharmacology 1997, 49:897-902.
11. Chae H.J., Park R.K., Kang J.S., Shin H.S., Kim S.C., Chung H.T., et al. Effect of stem cell factor, interleukin-6, nitric oxide and transforming growth factor-beta on the osteoclast differentiation induced by 1 alpha, 25-(OH)2D3 in primary murine bone marrow cultures. Pharmacology and Toxicology 1998, 82:223-229.
12. Chambliss K.L., Wu Q., Oltmann S., Konaniah E.S., Umetani M., Korach K.S., et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. Journal of Clinical Investigation 2010, 120:2319-2330.
13. Chen J.R., Plotkin L.I., Aguirre J.I., Han L., Jilka R.L., Kousteni S., et al. Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. Journal of Biological Chemistry 2005, 280:4632-4638.
14. Cheskis B.J., Greger J.G., Nagpal S., Freedman L.P. Signaling by estrogens. Journal of Cellular Physiology 2007, 213:610-617.
15. Chrischilles E.A., Butler C.D., Davis C.S., Wallace R.B. A model of lifetime osteoporosis impact. Archives of Internal Medicine 1991, 151:2026-2032.
16. Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: An endocrine cell... and more. Endocrine Reviews 2013, 34:658-690.
17. Danial N.N. BAD: Undertaker by night, candyman by day. Oncogene 2008, 27(Suppl. 1):S53-S70.
18. Datta S.R., Katsov A., Hu L., Petros A., Fesik S.W., Yaffe M.B., et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Molecular Cell 2000, 6:41-51.
19. Dong S.S., Williams J.P., Jordan S.E., Cornwell T., Blair H.C. Nitric oxide regulation of cGMP production in osteoclasts. Journal of Cellular Biochemistry 1999, 73:478-487.
20. Edwards J.R., Mundy G.R. Advances in osteoclast biology: Old findings and new insights from mouse models. Nature Reviews. Rheumatology 2011, 7:235-243.
21. Emerton K.B., Hu B., Woo A.A., Sinofsky A., Hernandez C., Majeska R.J., et al. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 2010, 46:577-583.
22. Fiscus R.R. Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells. Neurosignals 2002, 11:175-190.
23. Francis S.H., Busch J.L., Corbin J.D., Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacological Reviews 2010, 62:525-563.
24. Fuller K., Kirstein B., Chambers T.J. Murine osteoclast formation and function: Differential regulation by humoral agents. Endocrinology 2006, 147:1979-1985.
25. Grassi F., Fan X., Rahnert J., Weitzmann M.N., Pacifici R., Nanes M.S., et al. Bone re/modeling is more dynamic in the endothelial nitric oxide synthase(-/-) mouse. Endocrinology 2006, 147:4392-4399.
26. Hayashi T., Ito I., Kano H., Endo H., Iguchi A. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2000, 55:B183-B190.
27. Hofmann F., Bernhard D., Lukowski R., Weinmeister P. cGMP regulated protein kinases (cGK). Handbook of Experimental Pharmacology 2009, 191:137-162.
28. Hopkins R.B., Goeree R., Pullenayegum E., Adachi J.D., Papaioannou A., Xie F., et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 2011, 12:209.
29. Hukkanen M., Platts L.A., Lawes T., Girgis S.I., Konttinen Y.T., Goodship A.E., et al. Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 2003, 32:142-149.
30. Jamal S.A., Browner W.S., Bauer D.C., Cummings S.R. Intermittent use of nitrates increases bone mineral density: The study of osteoporotic fractures. Journal of Bone and Mineral Research 1998, 13:1755-1759.
31. Jamal S.A., Cummings S.R., Hawker G.A. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: A randomized trial. Journal of Bone and Mineral Research 2004, 19:1512-1517.
32. Jamal S.A., Hamilton C.J. Nitric oxide donors for the treatment of osteoporosis. Current Osteoporosis Reports 2012, 10:86-92.
33. Jamal S.A., Hamilton C.J., Eastell R., Cummings S.R. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: A randomized trial. Journal of the American Medical Association 2011, 305:800-807.
34. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 1992, 257:88-91.
35. Johlfs M.G., Fiscus R.R. Protein kinase G type-Ialpha phosphorylates the apoptosis-regulating protein Bad at serine 155 and protects against apoptosis in N1E-115 cells. Neurochemistry International 2010, 56:546-553.
36. Jung J.Y., Lin A.C., Ramos L.M., Faddis B.T., Chole R.A. Nitric oxide synthase I mediates osteoclast activity in vitro and in vivo. Journal of Cellular Biochemistry 2003, 89:613-621.
37. Khosla S. Is nitroglycerin a novel and inexpensive treatment for osteoporosis?. Journal of the American Medical Association 2011, 305:826-827.
38. Khosla S., Bellido T.M., Drezner M.K., Gordon C.M., Harris T.B., Kiel D.P., et al. Forum on aging and skeletal health: Summary of the proceedings of an ASBMR workshop. Journal of Bone and Mineral Research 2011, 26:2565-2578.
39. Khosla S., Melton L.J., Riggs B.L. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: Is a revision needed?. Journal of Bone and Mineral Research 2011, 26:441-451.
40. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
41. Kousteni S., Chen J.R., Bellido T., Han L., Ali A.A., O'Brien C.A., et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002, 298:843-846.
42. Krum S.A. Direct transcriptional targets of sex steroid hormones in bone. Journal of Cellular Biochemistry 2011, 112:401-408.
43. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO Journal 2008, 27:535-545.
44. Lee S.Y., Andoh T., Murphy D.L., Chiueh C.C. 17beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection. FASEB Journal 2003, 17:947-948.
45. Lee S.K., Huang H., Lee S.W., Kim K.H., Kim K.K., Kim H.M., et al. Involvement of iNOS-dependent NO production in the stimulation of osteoclast survival by TNF-α. Experimental Cell Research 2004, 298:359-368.
46. Levin E.R. Minireview: Extranuclear steroid receptors: Roles in modulation of cell functions. Molecular Endocrinology 2011, 25:377-384.
47. Li L., Hisamoto K., Kim K.H., Haynes M.P., Bauer P.M., Sanjay A., et al. Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16468-16473.
48. Mancini L., Moradi-Bidhendi N., Becherini L., Martineti V., MacIntyre I. The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent. Biochemical and Biophysical Research Communications 2000, 274:477-481.
49. Manolagas S.C. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocrine Reviews 2010, 31:266-300.
50. Manolagas S.C., Parfitt A.M. For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases. Bone 2013, 54:272-278.
51. Marathe N., Rangaswami H., Zhuang S., Boss G.R., Pilz R.B. Pro-survival effects of 17beta-estradiol on osteocytes are mediated by nitric Oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. Journal of Biological Chemistry 2012, 287:978-988.
52. Nabhan A.F., Rabie N.H. Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. International Journal of Gynaecology and Obstetrics 2008, 103:213-216.
53. Nathan C. The moving frontier in nitric oxide-dependent signaling. Science's STKE 2004, 2004:e52.
54. Nicolin V., Ponti C., Narducci P., Grill V., Bortul R., Zweyer M., et al. Different levels of the neuronal nitric oxide synthase isoform modulate the rate of osteoclastic differentiation of TIB-71 and CRL-2278 RAW 264.7 murine cell clones. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology 2005, 286:945-954.
55. Otsuka E., Hirano K., Matsushita S., Inoue A., Hirose S., Yamaguchi A., et al. Effects of nitric oxide from exogenous nitric oxide donors on osteoblastic metabolism. European Journal of Pharmacology 1998, 349:345-350.
56. Pouwels S., Lalmohamed A., van Staa T., Cooper C., Souverein P., Leufkens H.G., et al. Use of organic nitrates and the risk of hip fracture: A population-based case-control study. Journal of Clinical Endocrinology and Metabolism 2010, 95:1924-1931.
57. Raisz L.G. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. Journal of Clinical Investigation 2005, 115:3318-3325.
58. Rangaswami H., Marathe N., Zhuang S., Chen Y., Yeh J.C., Frangos J.A., et al. Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. Journal of Biological Chemistry 2009, 284:14796-14808.
59. Rangaswami H., Schwappacher R., Marathe N., Zhuang S., Casteel D.E., Haas B., et al. Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts. Science Signaling 2010, 3:ra91.
60. Rejnmark L., Vestergaard P., Mosekilde L. Decreased fracture risk in users of organic nitrates: A nationwide case-control study. Journal of Bone and Mineral Research 2006, 21:1811-1817.
61. Russell K.S., Haynes M.P., Sinha D., Clerisme E., Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:5930-5935.
62. Samuels A., Perry M.J., Gibson R.L., Colley S., Tobias J.H. Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. Bone 2001, 29:24-29.
63. Schlossmann J., Ammendola A., Ashman K., Zong X., Huber A., Neubauer G., et al. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP-dependent protein kinase. Nature 2000, 404:197-200.
64. Surks H.K., Mochizuki N., Kasai Y., Georgescu S.P., Tang K.M., Ito M., et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Iα. Science 1999, 286:1583-1587.
65. Tan S.D., Kuijpers-Jagtman A.M., Semeins C.M., Bronckers A.L., Maltha J.C., Von den Hoff J.W. Fluid shear stress inhibits TNFalpha-induced osteocyte apoptosis. Journal of Dental Research 2006, 85:905-909.
66. Tang K.M., Wang G., Lu P., Karas R.H., Aronovitz M., Heximer S.P., et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nature Medicine 2003, 9:1506-1512.
67. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metabolism 2007, 5:464-475.
68. Tomkinson A., Reeve J., Shaw R.W., Noble B.S. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. Journal of Clinical Endocrinology and Metabolism 1997, 82:3128-3135.
69. van't Hof R.J., Macphee J., Libouban H., Helfrich M.H., Ralston S.H. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 2004, 145:5068-5074.
70. Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.T., Hodgson S.F., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine Practice 2010, 16(Suppl. 3):1-37.
71. Weber S., Bernhard D., Lukowski R., Weinmeister P., Worner R., Wegener J.W., et al. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circulation Research 2007, 101:1096-1103.
72. Wimalawansa S.J. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. Journal of Bone and Mineral Research 2000, 15:2240-2244.
73. Wimalawansa S.J., De Marco G., Gangula P., Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996, 18:301-304.
74. Wimalawansa S.J., Grimes J.P., Wilson A.C., Hoover D.R. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. Journal of Clinical Endocrinology and Metabolism 2009, 94:3356-3364.
75. Yaroslavskiy B.B., Turkova I., Wang Y., Robinson L.J., Blair H.C. Functional osteoclast attachment requires inositol-1,4,5-trisphosphate receptor-associated cGMP-dependent kinase substrate. Laboratory Investigation 2010, 90:1533-1542.
76. Zhou X.M., Liu Y., Payne G., Lutz R.J., Chittenden T. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. Journal of Biological Chemistry 2000, 275:25046-25051.